<?xml version="1.0" encoding="UTF-8"?>
<p id="Par49">A candidate adenovirus vaccine named Ad5-nCoV, synthesized by CanSino Biologics Inc. (Tianjin, China) via recombinant technology, was subjected in March 2020 to a phase I safety clinical investigation involving 108 healthy individuals from Wuhan, China, with the study plan running to the end of 2020 [
 <xref ref-type="bibr" rid="CR41">41</xref>]. By March 2020, several other candidate vaccines were being quickly optimized and prepared for initial testing in human subjects [
 <xref ref-type="bibr" rid="CR11">11</xref>, 
 <xref ref-type="bibr" rid="CR22">22</xref>, 
 <xref ref-type="bibr" rid="CR38">38</xref>, 
 <xref ref-type="bibr" rid="CR39">39</xref>, 
 <xref ref-type="bibr" rid="CR42">42</xref>, 
 <xref ref-type="bibr" rid="CR43">43</xref>]. Several companies, educational research groups, and global alliances were involved in the initial levels of vaccine preparation, investigations at the laboratory level, or organizing phase I safety clinical trials to further improve candidate vaccines [
 <xref ref-type="bibr" rid="CR11">11</xref>, 
 <xref ref-type="bibr" rid="CR22">22</xref>, 
 <xref ref-type="bibr" rid="CR38">38</xref>, 
 <xref ref-type="bibr" rid="CR39">39</xref>]. The government of Canada is contributing a grant of CA $192 million for vaccine production and related research studies [
 <xref ref-type="bibr" rid="CR44">44</xref>].
</p>
